SCHEMBL1764124

SCHEMBL1764124

NP(O)O.c1ccc(C(OC(c2ccccc2)(c2ccccc2)c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.43
KCNN4 O15554 2/20 0.40
ALDH1A1 P00352 3/20 0.38
ALOX15 P16050 1/20 0.38
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
KCNH2 Q12809 1/20 0.37
MAPK1 P28482 1/20 0.36
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
TSHR P16473 2/20 0.35
CYP1A2 P05177 3/20 0.33
TAAR1 Q96RJ0 1/20 0.33
CYP2D6 P10635 1/20 0.32
ESR1 P03372 2/20 0.32
ESR2 Q92731 2/20 0.32
PTPN1 P18031 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8973 0.84 KIF11 (0.48) KIF11KCNN4ALDH1A1ALOX15CYP3A4
Bromide SCHEMBL28557682 0.82 KIF11 (0.46) KIF11KCNN4ALDH1A1ALOX15CYP3A4
Fluoride SCHEMBL27919232 0.82 KIF11 (0.46) KIF11KCNN4ALDH1A1ALOX15CYP3A4
SCHEMBL28297324 0.82 KIF11 (0.46) KIF11KCNN4ALDH1A1ALOX15CYP3A4
Hydrochloric Acid SCHEMBL28556207 0.82 KIF11 (0.46) KIF11KCNN4ALDH1A1ALOX15CYP3A4
Ammonia Solution, Strong SCHEMBL23726528 0.82 KIF11 (0.46) KIF11KCNN4ALDH1A1ALOX15CYP3A4
SCHEMBL1764122 0.79 KIF11 (0.42) KIF11KCNN4ALDH1A1ALOX15CYP3A4
Ethylene Glycol SCHEMBL11275979 0.78 KIF11 (0.45) KIF11KCNN4ALDH1A1ALOX15CYP3A4
Formaldehyde SCHEMBL27751011 0.77 KIF11 (0.43) KIF11KCNN4ALDH1A1ALOX15CYP3A4
SCHEMBL28958532 0.76 ESR1 (0.58) KIF11ALDH1A1ALOX15CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034798-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2015-05-19 US disclosed
US-8569481-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions PHARMACEUTICALS, INC. (US) 2013-10-29 US disclosed
US-20110118136-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions KOESTER HUBERT 2011-05-19 US disclosed
US-7858560-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2010-12-28 US disclosed
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-11-25 US disclosed
EP-1583972-B1 METHODS FOR IDENTIFYING DRUG NON-TARGET PROTEINS CAPROTEC BIOANALYTICS GMBH (DE) 2010-11-24 EP disclosed
US-20100248264-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-09-30 US disclosed
EP-2053406-A2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions caprotec bioanalytics GmbH (DE) 2009-04-29 EP disclosed
EP-1485707-B1 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS CAPROTEC BIOANALYTICS GMBH (DE) 2009-01-14 EP disclosed
EP-1502102-B1 COMPOUNDS AND METHODS FOR ANALYZING THE PROTEOME CAPROTEC BIOANALYTICS GMBH (DE) 2009-01-14 EP disclosed
EP-1502102-A2 COMPOUNDS AND METHODS FOR ANALYZING THE PROTEOME HK Pharmaceuticals, Inc. (US) 2005-02-02 EP disclosed
EP-1485707-A2 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK Pharmaceuticals, Inc. (US) 2004-12-15 EP disclosed
US-20040209255-A1 Compounds and methods for analyzing the proteome HK PHARMACEUTICALS, INC. 2004-10-21 US disclosed
WO-2004064972-A9 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK PHARMACEUTICALS INC (US) 2004-09-16 WO disclosed
WO-2004064972-A2 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK PHARMACEUTICALS, INC. (US) 2004-08-05 WO disclosed
WO-2003077851-A9 COMPOUNDS AND METHODS FOR ANALYZING THE PROTEOME HK PHARMACEUTICALS INC (US) 2004-05-21 WO disclosed
WO-2003092581-A9 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK PHARMACEUTICALS INC (US) 2004-02-19 WO disclosed
WO-2003092581-A2 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK PHARMACEUTICALS, INC. (US) 2003-11-13 WO disclosed
WO-2003077851-A2 COMPOUNDS AND METHODS FOR ANALYZING THE PROTEOME HK PHARMACEUTICALS, INC. (US) 2003-09-25 WO disclosed
US-20030119021-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118136-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions PTMS, QPCTL, SRMS KIF11 3167/4885KCNN4 4723/4885ALDH1A1 4360/4885
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CHLSN, PTMS, SRMS KIF11 2903/4885KCNN4 4860/4885ALDH1A1 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.